Abexinostat, a pan-HDAC inhibitor, was clinically active as monotherapy in a phase 2 study of patients with FL (ORR, 56%) or DLBCL (ORR, 31%) [76]. This evidence concerns the gene HDAC9 and diffuse large B-cell lymphoma.